PMID- 24769273
OWN - NLM
STAT- MEDLINE
DCOM- 20150413
LR  - 20140812
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 47
IP  - 12
DP  - 2014 Aug
TI  - Serum paraoxonase-1 activity is more closely related to HDL particle 
      concentration and large HDL particles than to HDL cholesterol in Type 2 diabetic 
      and non-diabetic subjects.
PG  - 1022-7
LID - S0009-9120(14)00182-9 [pii]
LID - 10.1016/j.clinbiochem.2014.04.013 [doi]
AB  - OBJECTIVES: We determined relationships of the anti-oxidative enzyme, 
      paraoxonase-1 (PON-1), with high density lipoprotein (HDL) subfractions, and 
      tested whether these relationships are stronger than those with HDL cholesterol 
      and apolipoprotein A-I (apoA-I) in subjects with and without type 2 diabetes 
      mellitus (T2DM). DESIGN AND METHODS: Serum PON-1 (arylesterase activity) and HDL 
      subfractions (nuclear magnetic resonance spectroscopy) were determined in 67 T2DM 
      patients and in 56 non-diabetic subjects. RESULTS: PON-1 activity, HDL 
      cholesterol and apoA-I were decreased in T2DM (all p<0.05). The HDL particle 
      concentration was unaltered, but large HDL particles, medium HDL particles and 
      HDL particle size were decreased, whereas small HDL particles were increased in 
      T2DM (all p<0.05). PON-1 was more closely related to HDL cholesterol than to 
      apoA-I (p=0.001). In turn, the positive relationship of PON-1 with the HDL 
      particle concentration and with large HDL particles was stronger than that with 
      HDL cholesterol (both p<0.01). The inverse relationship of PON-1 with T2DM was 
      only modestly attenuated by HDL cholesterol or HDL particle characteristics. 
      CONCLUSIONS: PON-1 activity is more closely related to the HDL particle 
      concentration or large HDL particles than to HDL cholesterol. Impaired PON-1 
      activity in T2DM is not to a considerable extent explained by altered HDL 
      subfraction levels.
CI  - Copyright (c) 2014 The Canadian Society of Clinical Chemists. Published by Elsevier 
      Inc. All rights reserved.
FAU - Dullaart, Robin P F
AU  - Dullaart RP
AD  - Department of Endocrinology, University of Groningen and University Medical 
      Center Groningen, Groningen, The Netherlands. Electronic address: 
      r.p.f.dullaart@umcg.nl.
FAU - Otvos, James D
AU  - Otvos JD
AD  - LipoScience Inc., Raleigh, NC, USA. Electronic address: jotvos@liposcience.com.
FAU - James, Richard W
AU  - James RW
AD  - Division of Endocrinology, Diabetology, Hypertension and Nutrition, University 
      Hospital Geneva, Switzerland. Electronic address: Richard.James@hcuge.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140421
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - 0 (Lipoproteins, HDL)
RN  - EC 3.1.8.1 (Aryldialkylphosphatase)
RN  - EC 3.1.8.1 (PON1 protein, human)
SB  - IM
MH  - Aged
MH  - Aryldialkylphosphatase/*blood
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*blood/enzymology
MH  - Female
MH  - Humans
MH  - Lipoproteins, HDL/*blood
MH  - Magnetic Resonance Spectroscopy
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - High density lipoprotein subfractions
OT  - High density lipoproteins
OT  - Paraoxonase-1 activity
OT  - Type 2 diabetes mellitus
EDAT- 2014/04/29 06:00
MHDA- 2015/04/14 06:00
CRDT- 2014/04/29 06:00
PHST- 2014/02/12 00:00 [received]
PHST- 2014/03/19 00:00 [revised]
PHST- 2014/04/11 00:00 [accepted]
PHST- 2014/04/29 06:00 [entrez]
PHST- 2014/04/29 06:00 [pubmed]
PHST- 2015/04/14 06:00 [medline]
AID - S0009-9120(14)00182-9 [pii]
AID - 10.1016/j.clinbiochem.2014.04.013 [doi]
PST - ppublish
SO  - Clin Biochem. 2014 Aug;47(12):1022-7. doi: 10.1016/j.clinbiochem.2014.04.013. 
      Epub 2014 Apr 21.